Foundayo's prescriber base expanded from about 8,000 to 36,000 in a single quarter

Eli Lilly's oral obesity and diabetes drug Foundayo, known by the molecule name orforglipron, saw its prescriber base grow nearly fivefold in one quarter, from about 8,000 clinicians to roughly 36,000, according to analyst coverage of the company's second-quarter disclosures ^[1][2]. Lilly has framed the growth as evidence that a once-daily pill without food or water restrictions can move obesity treatment out of specialist clinics and into routine primary care visits ^[1].

The prescriber count is a leading indicator, not a measure of how many people are actually taking the drug. More doctors writing prescriptions does not by itself tell readers how many patients filled those prescriptions, stayed on the drug, or found it affordable ^[1]. Lilly has said it plans to expand Foundayo internationally in 2027, which would extend the drug beyond its current U.S. footprint ^[1][2].

The expansion comes as Lilly's broader GLP-1 business keeps growing. Second-quarter revenue reached $22.974 billion, up nearly 48% from a year earlier, and the company raised its full-year 2026 revenue guidance to between $85 billion and $87 billion ^[1]. Mounjaro and Zepbound, Lilly's injectable tirzepatide products, still account for the bulk of that revenue, with the two together posting close to $14.9 billion in one quarter and taking roughly six in ten U.S. obesity prescriptions overall ^[1][2]. One analyst estimated Mounjaro and Zepbound account for about seven in ten injectable obesity prescriptions specifically ^[2].

Analysts covering the stock cite the Foundayo prescriber growth as one reason they expect Lilly's incretin drug franchise to keep expanding for years. Citi, for example, pointed to the prescriber jump alongside a planned 2027 international rollout as part of its case for a higher stock price target ^[2]. But the same coverage notes that U.S. realized prices for Lilly's GLP-1 drugs fell roughly 9% to 13% in the quarter, excluding rebate adjustments, a sign that competition and payer pressure are already affecting the market Foundayo is entering ^[1][2].

Why it matters for patients

A sharp rise in the number of doctors willing to prescribe Foundayo suggests more patients may have a nearby option who can write for a daily pill instead of a weekly injection. Because Foundayo does not require food or water timing restrictions, it may fit more easily into primary care visits than some other GLP-1 options, which is the argument Lilly has made to investors ^[1]. That could mean shorter waits for a prescription for people who might otherwise need a referral to an obesity medicine specialist.

At the same time, a bigger prescriber base is not the same as easier or cheaper access. The sources describe prescriber counts as a leading indicator only, meaning they hint at future volume without confirming it ^[1]. Whether insurance plans cover Foundayo, what patients pay out of pocket, and how many people actually start and stay on the drug are separate questions the sources do not answer for this specific medicine.

The broader pricing trend in the sources, a roughly 9% to 13% drop in realized U.S. prices for Lilly's GLP-1 lineup, suggests the market is shifting as more options become available, though it is not clear from these sources how that trend will apply to Foundayo specifically once it reaches full commercial scale ^[1][2].

What happens next

Lilly has said it plans to launch Foundayo internationally in 2027, which would expand access to patients outside the United States ^[1][2]. The company's retatrutide obesity drug is expected to have a biologics license application submitted in the first quarter of 2027, a separate development that could add another treatment option to the market ^[1][2]. Neither source specifies a date for when U.S. prescriber growth might translate into published U.S. prescription volume figures for Foundayo.